Valneva (VALN) has released an update.
Valneva SE, a leading specialty vaccine company, announced the unanimous approval of all board-recommended resolutions at its Combined General Meeting, including the endorsement of the 2023 financial statements and the strategic appointment of Ms. Danièle Guyot-Caparros as a new director. Ms. Guyot-Caparros brings extensive finance and pharmaceutical industry experience to Valneva’s Board of Directors. The company, known for marketing the first chikungunya vaccine and developing the only advanced candidate for Lyme disease, reaffirms its commitment to addressing unmet medical needs with its specialized vaccine portfolio.
For further insights into VALN stock, check out TipRanks’ Stock Analysis page.
